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Abstract 
Aims. Fenofibrate may lower long-term cardiovascular events. The biological 
mediators of its mechanisms of action are not fully understood.  The current study 
aimed to determine whether the cardioprotective effects of fenofibrate are partly 
mediated through its uric acid (UA) lowering effects.  
Methods. Data from the Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD) trial was utilised, comprising 9795 adults with type 2 diabetes (T2D) randomly 
allocated to treatment with fenofibrate or matching placebo. Plasma UA was measured 
before and after a 6-week active fenofibrate run-in phase in all participants. Cox 
proportional hazards models were used to explore the relationships between baseline 
UA, pre-to-post run-in reductions in UA and long-term cardiovascular outcomes.   
Results. Mean baseline plasma UA was 0.33 mmol/L (SD 0.08). Baseline UA was a 
significant predictor of long-term cardiovascular events with every 0.1 mmol/L higher 
UA conferring a 21% increase in event rate (HR 1.21, 95% CI 1.13-1.29, p<0.001). 
This remained significant after adjustment for treatment allocation, cardiovascular risk 
factors, and renal function. The extent of UA reduction during fenofibrate run-in was 
also significant predictor of long-term cardiovascular events, with every 0.1 mmol/L 
greater reduction conferring a 14% lower long-term risk (HR 0.86, 95% CI 0.76-0.97, 
p = 0.015). This effect was not modified by treatment allocation (pinteraction = 0.77).  
Conclusions. UA is a strong independent predictor of long-term cardiovascular risk 
in adults with T2D. Although greater reduction in UA on fenofibrate is predictive of 
This article is protected by copyright. All rights reserved.
lower cardiovascular risk, this does not seem to mediate the cardioprotective effects 
of fenofibrate.  
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Introduction 
The degree of dyslipidaemia in type 2 diabetes (T2D) is closely linked to the risk of 
cardiovascular disease 1.. The Fenofibrate Intervention and Event Lowering in 
Diabetes (FIELD) trial demonstrated reduction in total cardiovascular disease events 
with fenofibrate compared to matching placebo in patients with type 2 diabetes over a 
median 5 years follow up 2. However, the mechanisms by which fenofibrate lowers 
cardiovascular event are not fully elucidated. Fibrates seem to have both lipoprotein 
related and non-lipoprotein related effects 3. Previous statin trials have demonstrated 
positive relationships between the extent of low-density lipoprotein (LDL) cholesterol 
lowering and reduction in cardiovascular events 4. In contrast, despite fenofibrate 
reducing triglyceride and increasing high-density lipoprotein (HDL) cholesterol levels, 
there are only weak correlations between improvements in lipid parameters and long-
term clinical cardiovascular benefits, thereby prompting ongoing search for biological 
mediators.  
Amongst the lipid-lowering agents, fenofibrate uniquely lowers circulating uric acid 
(UA) levels through increased renal clearance 5, and has been shown to be potentially 
a powerful adjunct in the treatment of gout 6. Previous post hoc analysis of the FIELD 
trial demonstrated that fenofibrate efficiently lowers UA  levels during the pre-
randomisation 6-week fenofibrate run-in phase, and maintains this level in those 
subsequently allocated to fenofibrate vs. placebo 6. Therefore, short-term change in 
UA levels is a reliable marker of long-term fenofibrate effects, and can be used to 
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investigate the potential mediating role of UA in fenofibrate-related cardiovascular 
benefits.  
In at least two large epidemiological studies, circulating UA levels have been reported 
to be a predictor of long-term cardiovascular events, independent of traditional risk 
factors 7,8, although such results have not been replicated in other studies 9,10. 
Additionally, the predictive ability of UA in those at high risk, such as patients with T2D, 
has not been reported. 
The current post hoc analysis of the FIELD trial had two aims. Firstly, we aimed to 
explore the relationship between baseline UA levels and long-term cardiovascular 
events in adults with T2D. Secondly, we aimed to examine whether the cardiovascular 
benefits of fenofibrate are mediated through its UA lowering properties.  
 
Methods 
Study Design and Participants 
The FIELD trial was a randomised double-blind placebo-controlled trial of fenofibrate 
in adults with T2D. The trial protocol and primary results have been previously 
published 2,11 (CONSORT Flow Diagram in Appendix 1). Briefly, patients with T2D 
aged between 50-75 years were screened. To qualify for study entry, patients were 
required to have a baseline plasma total-cholesterol concentration of between 3.0 
mmol/L to 6.5 mmol/L, plus either a total/HDL cholesterol ratio of 4·0 or more or a 
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plasma triglyceride concentration of between 1·0 mmol/L to 5·0 mmol/L. Patients were 
excluded on the basis of 1) being on or having indications for lipid-lowering therapy at 
study entry; 2) renal impairment (plasma creatinine ≥ 130 μmol/L); 3) chronic liver 
disease or symptomatic gallbladder disease; and 4) cardiovascular event 3 months 
prior to recruitment.  
All participants provided written informed consent, and the FIELD study protocol was 
approved by local and national ethics committees in accordance with the Declaration 
of Helsinki and Good Clinical Practice guidelines. 
Procedures 
All recruited participants underwent a 16-week run-in phase consisting of in order four 
weeks of lifestyle and dietary modifications, six weeks of single-blind placebo run-in 
and six weeks of single-blind fenofibrate run-in. The participants were subsequently 
randomised via a central computer, with stratification for important prognostic 
variables, into receiving either 200 mg daily of co-micronised fenofibrate or matching 
placebo. The participants were followed up for a median five years after 
randomisation. 
Plasma UA was measured immediately prior to fenofibrate run-in (baseline) and prior 
to randomisation. Short-term change in UA with fenofibrate was calculated by taking 
the difference between the baseline and pre-randomisation levels. Additionally, a 
random cohort of 2,000 subjects was selected for a third measurement one year after 
randomisation. All plasma UA concentrations were measured in stored samples after 
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study closure in a single central laboratory using a Cobas uricase enzymatic analyser 
(Roche, Mannheim). 
The primary results of the FIELD trial have previously been published 2. Briefly, 
fenofibrate treatment compared to matching placebo did not reduce the primary 
endpoint (first myocardial infarction or coronary heart disease death combined), but 
did reduce the prespecified secondary endpoint – total cardiovascular disease events 
(HR 0.89, 95% CI 0.80-0.99, p = 0.035). Total cardiovascular events were used as the 
outcome of interest for the present analyses to maximise the event rate. This was a 
composite of cardiovascular death, myocardial infarction, stroke, and coronary and 
carotid revascularisation.  
Other covariates of interest include treatment allocation, gender, age, prior 
cardiovascular disease (history of myocardial infarction, angina, coronary 
revascularisation, stroke, claudication, peripheral vascular disease or peripheral 
revascularisation), smoking status, renal function and baseline body mass index 
(BMI), systolic blood pressure, HbA1c and non-HDL cholesterol. Renal function was 
explored using the estimated glomerular filtration rate (eGFR), urinary albumin-to-
creatinine ratio and a combination thereof (eGFR ≥ or < 60 mL/min and presence or 
absence of albuminuria). All other variables were defined in accordance to the original 
FIELD trial 2.  
Statistical Analysis 
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Baseline UA levels were divided into gender-specific tertiles. Categorical or 
continuous variables were compared between tertiles using appropriate univariate 
trend tests including linear-by-linear test and one-way ANOVA with linear contrast. 
The baseline UA and cumulative cardiovascular event frequency over median five 
year follow-up were also presented according to the number of metabolic syndrome 
components as defined by the Adult Treatment Panel III 12. Furthermore, baseline UA 
level and prevalence of metabolic syndrome and its components were presented 
according to quintiles of cardiovascular risk using a previously derived model based 
on the FIELD data (Appendix 2).   
Survival analysis with Kaplan-Meier curves and log-rank test was conducted 
comparing long-term cardiovascular events between the baseline UA tertiles. Cox 
proportional hazards model was used to assess the changes in the risk of 
cardiovascular events for every 0.1 mmol/L higher baseline UA. The model was further 
adjusted for traditional cardiovascular risk factors at baseline including treatment 
allocation, age, gender, smoking, systolic blood pressure, HbA1c, triglyceride, non-
HDL cholesterol, prior cardiovascular disease and renal function. Subgroup analyses 
by important baseline prognostic factors were also undertaken to explore potential 
modifiers of the relationship between baseline UA and long-term cardiovascular 
events.    
Cox proportional hazards model was used to assess the relationship between 
reduction in UA levels before and after the 6-week active fenofibrate run-in and long-
term cardiovascular events, adjusting for randomised treatment allocation and 
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baseline UA levels. To explore drivers of this relationship, post hoc analyses were 
performed by sequentially adjusting one variable (e.g., gender, renal function, HbA1c 
etc.) further to the model above.  
Analyses of the relationships between total cardiovascular events and baseline and 
short-term change in UA levels were performed in accordance with an a priori 
statistical analyses plan. A two-sided p value was considered significant without 
adjustment for multiple testing. Initial analyses (by JYC) using SPSS 23 (IBM, IL, USA) 
and confirmed independently (RO’C and NA) using SAS 9.4 (SAS Institute, NC, USA). 
The FIELD study is registered with ISRCTN, number ISRCTN64783481. 
 
Results 
Of the 9795 participants who underwent randomisation to either fenofibrate or 
matching placebo, baseline UA data were available for 9622 participants (n=4807 
fenofibrate, n=4815 placebo).  
Baseline UA levels ranged 0.11-0.79 mmol/L for the entire cohort (mean 0.33 mmol, 
SD 0.08 mmol/L; Fig. 1). The baseline level for males was higher than for females 
(male: range 0.12-0.79 mmol/L, mean 0.34 mmol/L, SD 0.076 mmol/L; female: range 
0.11-0.71 mmol/L, mean 0.32 mmol/L, SD 0.079 mmol/L; p<0.001). The gender-
specific thresholds for lowest-to-middle, and middle-to-highest tertile were 0.30 and 
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0.36 mmol/L respectively in males, and 0.27 mmol/L and 0.34 mmol/L respectively in 
females.  
Baseline cardiovascular risk factors and cardiovascular disease were more prevalent 
in the highest UA tertile compared to the middle and lowest UA tertiles (Table 1). 
History of cardiovascular disease was noted in 24% of participants in the highest 
tertile, compared to 20% in the middle and lowest tertiles (p<0.001). Dyslipidaemia, 
defined as low HDL-C (male: < 1.03 mmol/L; female: < 1.29 mmol/L) and high 
triglyceride (≥ 1.7 mmol/L), was seen in 45% of participants in the highest tertile 
compared to 39% in the middle tertile and 30% in the lowest tertile (p<0.001). 
Accordingly, triglyceride levels were highest in the highest UA tertile and lowest in the 
lowest UA tertile (p<0.001). HbA1c had an inverse relationship to baseline UA levels, 
whereby HbA1c was the lowest in the highest UA tertile (6.6%) and highest in the 
lowest UA tertile (7.3%) (p<0.001). Baseline UA increased with the number of 
metabolic syndrome components (ptrend<0.001; Appendix 3). When stratified by 
quintiles of five-year cardiovascular risk, there was a linear increase in the prevalence 
of hypertension, high triglyceride, low HDL-C, and metabolic syndrome status, as well 
as baseline UA levels (ptrend<0.001 in all cases; Appendix 4). Allopurinol usage was 
the highest in the lowest UA tertile, while diuretic usage was highest in the highest UA 
tertile. This likely reflects inherent UA-related lowering and elevating effects of 
allopurinol and of diuretics respectively. Use of these drugs did not modify the 
relationship between baseline uric acid and cardiovascular disease (allopurinol: 
pinteraction = 0.27; diuretics: pinteraction = 0.39).  
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Baseline Uric Acid and Cardiovascular Events 
There were 395 (12.2%), 428 (13.3%) and 453 (14.3%) onstudy cardiovascular events 
in the lowest, middle and highest baseline UA tertiles respectively over median 5 year 
follow up. As shown in Figure 3, Kaplan-Meier analysis revealed significant differences 
in rates of cardiovascular events (log rank: χ2=6.64, p=0.036), by baseline UA levels 
(Fig. 2).  
Cox-proportional hazards model demonstrated a 21% increase in cardiovascular 
events with every 0.1 mmol/L higher baseline UA (HR 1.21, 95% CI 1.13-1.29, 
p<0.001; Table 2). This corresponded to 16% change in risk for every one standard 
deviation change in UA levels, or 30% increase in risk from the median of the lowest 
UA tertile to the median of the highest tertile. Similar risks were seen by different 
periods of follow up (1-year: HR 1.19, 95% CI 1.01-1.40, p = 0.039; 3-year: HR 1.20, 
95% CI 1.09-1.31, p < 0.001; 5-year: HR 1.18, 95% CI 1.10-1.27, p < 0.001). Subgroup 
analyses revealed that higher baseline UA levels were associated with a smaller 
increase in on-trial cardiovascular events in those with systolic BP>140 mmHg or non-
HDL-cholesterol over median than otherwise (pinteraction=0.04 and 0.03 respectively; 
Appendix 5). No other interactions were noted between baseline UA and important 
prognostic variables on cardiovascular events.  
Baseline UA levels were associated with multiple baseline cardiovascular prognostic 
variables (Appendix 6). After adjustment for these variables, baseline UA remained a 
significant predictor of long-term cardiovascular events, with every 0.1 mmol/L higher 
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UA level conferring a 9% increased risk (Table 2). On subgroup analysis of only 
participants not taking allopurinol or diuretics at baseline, UA remained a significant 
predictor of long-term cardiovascular disease (HR 1.17, 95% CI 1.08-1.27, p < 0.001). 
Short-Term Change in Uric Acid and Cardiovascular Events  
Data for short-term change in UA with 6-week single-blind fenofibrate run-in were 
available in 9347 participants (Appendix 7). A mean decrease in UA of 0.07 mmol/L 
(SD 0.05) was noted, corresponding to a 22% decrease from pre-run-in to pre-
randomisation level. The reduction in UA on fenofibrate was greater in females than 
males (female: mean 0.073 mmol/L, SD 0.05; male: mean 0.067 mmol/L, SD 0.05; p 
< 0.001).  
The effect of long-term fenofibrate treatment on long-term cardiovascular events was 
analysed according to the extent of UA reduction during run-in as being above or 
below the median (0.07 mmol/L). This was undertaken on the rationale that if UA 
reduction mediated the cardiovascular effects of fenofibrate, then those experiencing 
a greater reduction in UA during run-in would also derive a greater cardiovascular 
benefit on fenofibrate in the long-term (i.e. a lower HR). This was not observed – the 
cardiovascular effect of fenofibrate was comparable between those experiencing a 
greater and lesser UA reduction during run-in (pinteraction = 0.53, Fig. 3A) 
Adjusted for treatment allocation and baseline UA level, the short-term fenofibrate-
induced change in UA was significantly associated with long-term cardiovascular 
events, with every 0.1 mmol/L greater reduction conferring a 14% lower long-term risk 
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(HR 0.86, 95% CI 0.76-0.97, p = 0.015; Fig. 3B). There was no interaction between 
short-term change in UA levels on fenofibrate and treatment allocation with regards to 
long-term cardiovascular events (pinteraction = 0.77). This was confirmed by subgroup 
analyses by treatment allocation showing short-term change in UA levels was 
associated with on-trial cardiovascular events both in the fenofibrate (HR 0.87, 95% 
CI 0.73-1.04, p = 0.12) and matching placebo groups (HR 0.85, 95% CI 0.72-1.01, p 
= 0.06), although neither was statistically significant. Post hoc analyses with additional 
variable adjustment to above model did not indicate modification of the relationship 
between short-term change in UA and long-term cardiovascular risk except by gender 
(Appendix 8). Notably, short-term reduction in UA was no longer associated with on-
trial cardiovascular events after adjusting for baseline UA levels, treatment allocation 
and gender (HR 0.94, 95% CI 0.83-1.07, p = 0.33). When applied to each gender 
separately, a trend was identified between baseline UA levels and long-term 
cardiovascular events in females (HR 0.78, 95% CI 0.61-1.01, p = 0.05), but not in 
males (HR 1.00, 95% CI 0.86-1.15, p = 0.95), although the interaction term was not 
significant (pinteraction = 0.10).   
Change in UA levels during the active fenofibrate run-in period associated significantly 
with various baseline and other run-in change variables, although the strength of 
association was stronger with the baseline UA levels (Appendix 9). This was confirmed 
on multi-variable linear regression showing a 0.032 mmol/L higher reduction in UA 
levels with every 1 SD higher baseline UA (p < 0.001; Appendix 10).   
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Discussion 
UA is an emerging risk factor for cardiovascular disease in many, but not all, 
populations 7,8,13, and is established as a component of the metabolic syndrome.  
However, the strength and relationship between UA levels and cardiovascular risk 
factors, in people with T2D is not fully elucidated. Various studies report linear, 
curvilinear and even U-shaped relationships between UA levels and chronic diabetes 
complications 14,15. The current very large study in the robust FIELD trial of well-
characterised adults with Type 2 diabetes demonstrated that baseline plasma UA 
levels are independently associated with on-trial cardiovascular events, with every 0.1 
mmol/L higher UA level predicting a 21% increase in risk. UA levels were related to 
the number of components of the metabolic syndrome. This relationship remained 
statistically significant after adjusting for traditional risk factors and renal function. The 
current study further explored whether the cardiovascular benefits of fenofibrate 
beyond its lipid effects are mediated at least partly through its UA-lowering properties. 
Short-term (6-weeks) exposure to fenofibrate reduced UA levels and was inversely 
associated with on-trial cardiovascular events i.e. those with greater UA reductions 
had lower event rates.  
High levels of UA, the end-product of purine catabolism are strongly linked with gout 
and nephrolithiasis. Its links with cardiometabolic diseases, including obesity, 
hypertension 16, diabetes 17-19, metabolic syndrome 20,21, heart failure 22-24 and 
ischaemic heart disease 25 are recognised, but underlying mechanisms are not well-
established. The First National Health and Nutrition Examination Survey found that in 
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nearly 6,000 subjects followed up for a mean 16 years, baseline UA independently 
predicted ischaemic heart disease mortality and cardiovascular mortality 7. Notably, 
however, only 2% of the cohort had T2D at baseline. Studies examining the 
relationship between UA levels and cardiovascular risk exclusively in patients with 
T2D have yielded contrasting results 26-28. This is likely a product of limited cohort size 
(approximately 1200-2700 patients) and between-study differences in the method of 
adjustment for important baseline risk factors, including gender, glycaemic control and 
renal function. A meta-analysis of T2D studies demonstrated a small but statistically 
significant 28% increase in risk of macrovascular complications  per 0.1 mmol/L higher 
UA levels in 20,981 patients with T2D 29. However, the net effect was driven by 
peripheral vascular disease rather than cerebrovascular or coronary heart disease.  
The current analysis to our knowledge is the largest exploration of the relationship 
between UA and cardiovascular outcomes in patients with T2D. At baseline, history of 
cardiovascular disease and presence of cardiovascular risk factors were shown to be 
most prevalent in the highest baseline UA tertile, with the only exception being HbA1c, 
which had an inverse relationship to UA levels. This relationship has been reported in 
various large epidemiological studies, showing that serum UA levels rise with glucose 
levels to a certain point, then begin to decrease with worsening glycaemia.  
 
On-study cardiovascular events was also associated with higher baseline UA levels, 
even after adjustment for multiple clinical and biochemical risk factors, including 
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baseline renal function and HbA1c. The magnitude of the relationship was potentially 
modified by baseline systolic blood pressure and non-HDL cholesterol levels, whereby 
in those with worse hypertension and higher non-HDL cholesterol, baseline UA was 
less strongly (but still significantly) associated with subsequent cardiovascular events. 
However, this should be taken in the context of lack of statistical adjustment for 
multiple testing. Even though UA levels are usually higher in men than women,  
previous epidemiological studies have identified a stronger association between UA 
and subsequent cardiovascular events in women than men 7. The current analysis did 
not identify any differences between the two genders (p for interaction effect = 0.5). 
This may be influenced by our FIELD female participants predominantly being post-
menopausal, and that in T2D, the female gender-related protection against 
cardiovascular disease is lost 30.  
The FIELD trial demonstrated an 11% reduction in the prespecified secondary 
outcome of total cardiovascular events in the fenofibrate vs. placebo group 2. 
Fenofibrate has been shown to have non-lipid related effects on inflammatory and 
thrombotic processes 31, one which is increased renal clearance of UA. The current 
study found that long-term fenofibrate cardiovascular benefits did not differ between 
those experiencing greater and lesser UA reductions during fenofibrate run-in (p for 
interaction effect = 0.53), suggesting that UA lowering does not mediate the fenofibrate 
cardiovascular benefits. This was confirmed by the fact that short-term fenofibrate-
induced reduction in UA during active run-in was associated with long-term 
cardiovascular benefits, although this relationship did not differ between those 
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subsequently allocated to long-term fenofibrate or control (p for interaction effect = 
0.77). Notably, in those who were allocated to long-term fenofibrate, the mean UA 
level at one  year post-randomisation  was similar to  the post-run-in level 6, meaning 
that the run-in change is an adequate surrogate for long-term change. Similar findings 
were noted in the Greek Atorvastatin and Coronary Heart Disease Evaluation Study, 
where a 5% reduction in UA over a mean 3-year follow up predicted a 15% reduction 
in risk of vascular events in those with metabolic syndrome and coronary artery 
disease. It is unclear, however, if the cardioprotective benefits of atorvastatin were 
mediated through UA lowering 32.   
Interestingly, post hoc analyses to determine the drivers of the relationship between 
reduction in UA by short-term fenofibrate and long-term cardiovascular outcomes 
revealed that the relationship was largely unaltered by further adjustment for baseline 
renal function, cardiovascular risk factors, smoking status and prior cardiovascular 
disease. Rather, the relationship appeared to have been driven by the strong trend 
towards benefit (p= 0.055) that females experience with every 0.1 mmol/L greater 
short-term reduction in UA levels conferring a 22% lower cardiovascular risk over five 
years. In contrast, the relationship between short-term reduction in UA and 
cardiovascular risk was not present in males (HR = 1.0). Previous analyses of FIELD 
data have also noted more favourable lipoprotein improvements on fenofibrate in 
females than males 33. Nevertheless, gender was not a statistically significant effect 
modifier of the relationship between UA reductions with short-term fenofibrate and 
cardiovascular risk (p for interaction effect = 0.10).  
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The current study needs to be interpreted in the context of several limitations. Firstly, 
there was a narrow spectrum of renal disease due to the FIELD trial excluding any 
participants with serum creatinine >130 μmol/L. Since fenofibrate-induced UA-
lowering is mediated through increased renal excretion of UA, exploration of current 
results across a wider range of renal function would be of clinical utility. Furthermore, 
as the study excluded patients with severe renal impairment, this may increase the 
probability of including more overproducers of UA, and therefore observing a clinical 
benefit with fenofibrate-mediated UA lowering 34,35. Secondly, being a retrospective 
analysis, whether the relationship between UA and cardiovascular risk is causal or 
correlational could not be fully defined. However, the association between UA and 
baseline cardiovascular risk factors and on-study cardiovascular events, even after 
adjustment for multiple other risk factors, should prompt consideration of UA as a 
causal mechanism 36. Thirdly, the current study analysed UA in plasma, which is less 
commonly used than serum in clinical practice, however, the analytical method using 
a Cobas enzymatic analyser has been validated for both plasma and serum UA 
analyses.  
In conclusion, baseline UA levels and the changes therein after short-term fenofibrate 
use are both independent associates of subsequent cardiovascular events in patients 
with T2D. However, the UA lowering alone does not fully account for all of fenofibrate’s 
cardiovascular benefits. 
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Figure Legends 
 
Figure 1. Frequency histogram of baseline plasma uric acid (n=9622), divided into 
gender-specific tertiles with individual tertile ranges for both genders shown by bars 
above the histogram (male: n=6042; female: n=3580). * Uric acid treatment target in 
non-tophaceous gout (0.36 mmol/L) recommended by European League Against 
Rheumatism. The shaded red column represents the mean baseline uric acid (0.32 
mmol/L).  
 
Figure 2. Cardiovascular event by tertiles of baseline uric acid. Cumulative rate of 
total cardiovascular events over median 5 years follow-up presented next to figure 
legend.  
 
Figure 3. A) Hazard ratio for long-term cardiovascular events on fenofibrate 
compared to control, stratified by absolute UA reduction during fenofibrate run-in. UA 
reduction was grouped as greater than or equal to median (0.07 mmol/L), or less 
than median, as represented by the top two bars. B) Hazard ratio for long-term 
cardiovascular events for every 0.1 mmol/L run-in reduction in plasma uric acid on 
fenofibrate (adjusted for baseline uric acid and long-term treatment allocation). The 
interval marks are 0.1-unit increments between HR 0.5-1, and 1-unit increments 
between HR 1-5. HR = hazard ratio. UA = uric acid  
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 Lowest Tertile (n=3248) 
Levels  
Middle Tertile (n=3206) 
Levels 
Highest Tertile (n=3168) 
Levels 
p value 
Baseline uric acid, mmol/L  0.26 (0.23-0.28) 0.33 (0.31-0.34) 0.40 (0.38-0.44) < 0.001 
Gender, male (%) 2107 (65) 1941 (61) 1994 (63) 0.11 
Age, years 62 (6) 62 (6.9) 63 (6.9) < 0.001 
Ethnicity 
  Caucasian 
  Asian 














Clinical history (%) 
  Previous cardiovascular disease 
  Hypertension 
  Metabolic syndrome 
  Smoking 
    Non-smoker 
    Ex-smoker 
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  Uricosurics 
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  Pulse pressure, mmHg 










  Total cholesterol, mmol/L 
  Triglyceride, mmol/L 
  LDL-C, mmol/L 
  HDL-C, mmol/L 
  Non-HDL-C, mmol/L 
  Dyslipidaemia † (%) 
  HbA1c, % 
  eGFR, mL/min/1.73 m2 
  eGFR < 60 mL/min/1.73 m2 (%) 
  Albuminuria (%) 
    Normal 
    Microalbuminuria †† 























































Table 1. Baseline clinical and laboratory variables between baseline uric acid tertiles. Trend tests are used to derive all p values. 
Continuous outcomes are reported as mean (SD) if normally distributed and median (IQR) if not normally distributed. eGFR = 
estimated glomerular filtration rate. HDL-C = high density lipoprotein cholesterol. LDL-C = low density lipoprotein cholesterol. 
†Dyslipidaemia was defined as low HDL-C (male: < 1.03 mmol/L; female: < 1.29 mmol/L) and high triglyceride (≥ 1.7 mmol/L). 
††Microalbuminuria was defined as urinary albumin-to-creatinine ratio 2.5-25 in male or 3.5-35 in female. †††Macroalbuminuria was 
defined as urinary albumin-to-creatinine ratio > 25 in male or > 35 in female.  
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 Unadjusted p value Adjusted p value  
Baseline uric acid (per 0.1 mmol/L) 1.21 (1.13-1.29) < 0.001 1.09 (1.01-1.18) 0.020 
Age (y)   1.04 (1.03-1.05) < 0.001 
Gender  
  Male† 
  Female 







  Placebo† 
  Fenofibrate 






Baseline BMI (kg/m2)   1.00 (0.99-1.02) 0.49 
Prior CVD 
  No† 
  Yes 







  Non-smoker† 
  Ex-smoker 
  Current smoker 








Baseline systolic BP (per 10 mmHg)   1.10 (1.06-1.14) < 0.001 
HbA1c (per 1 %)   1.13 (1.08-1.18) < 0.001 
Baseline triglycerides (per 1 mmol/L)   1.03 (0.97-1.10) 0.33 
Baseline non-HDL-C (per 1 mmol/L)   1.28 (1.17-1.39) < 0.001 
Composite eGFR/albuminuria 
  eGFR ≥ 60, no albuminuria 
  eGFR < 60, no albuminuria 
  eGFR ≥ 60, albuminuria 
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  eGFR < 60, albuminuria 1.82 (1.42-2.33) < 0.001 
 
Table 2. Unadjusted and adjusted (for each listed variable) Cox proportional models of baseline uric acid as a predictor of 
cardiovascular events (HR for every 0.1 mmol/L higher baseline uric acid). † Reference group. * p < 0.05 for continuous variables or 
p < 0.05 compared to reference group for categorical variables. 95% confidence interval presented in parentheses after each 
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